06 March 2017

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that it has filed a new formulation patent with the UK Intellectual Property Office in connection with MED2002, the Company's novel topical gel for the treatment of erectile dysfunction.

This patent application has the potential to extend MED2002's patent life worldwide through to 2038, thereby significantly increasing the opportunity for licensing partners to generate higher revenues and profits from the commercialisation of MED2002.

The new patent includes intellectual property confirmed by the Company's pivotal efficacy study of MED2002, the results of which were announced in September 2016.

MED2002's current patent protection runs until August 2028 in the USA and August 2025 in Europe.

James Barder, Futura's Chief Executive, commented: "This latest patent filing has the potential to extend MED2002's patent protection worldwide through to 2038, significantly extending the product's commercial window and increasing its attractiveness to licensing partners."

This announcement contains inside information.


For further information please contact:

Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
+44 (0) 1483 685 670

Nominated Adviser:
N+1 Singer
Aubrey Powell / Liz Yong
Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Mark Court / Sophie Wills /
Stephanie Watson / Tilly Abraham
Tel: +44 (0) 20 7466 5000


Notes to editors:

About Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange (AIM: FUM).